{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:09:02Z","timestamp":1793383742024,"version":"4.5.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,2,8]],"date-time":"2016-02-08T00:00:00Z","timestamp":1454889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,2,8]],"date-time":"2016-02-08T00:00:00Z","timestamp":1454889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1038\/leu.2016.12","type":"journal-article","created":{"date-parts":[[2016,2,8]],"date-time":"2016-02-08T07:41:22Z","timestamp":1454917282000},"page":"1018-1024","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":161,"title":["Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both"],"prefix":"10.1038","volume":"30","author":[{"given":"S","family":"Koschmieder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T I","family":"Mughal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H C","family":"Hasselbalch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Barosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Valent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J-J","family":"Kiladjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Jeryczynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Gisslinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J S","family":"Jutzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H L","family":"Pahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Hehlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Maria Vannucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Cervantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R T","family":"Silver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Barbui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,2,8]]},"reference":[{"key":"BFleu201612_CR1","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s12185-012-1235-2","volume":"97","author":"JD Milosevic","year":"2013","unstructured":"Milosevic JD, Kralovics R . Genetic and epigenetic alterations of myeloproliferative disorders. Int J Hematol 2013; 97: 183\u2013197.","journal-title":"Int J Hematol"},{"key":"BFleu201612_CR2","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013; 369: 2379\u20132390.","journal-title":"N Engl J Med"},{"key":"BFleu201612_CR3","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","volume":"369","author":"J Nangalia","year":"2013","unstructured":"Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013; 369: 2391\u20132405.","journal-title":"N Engl J Med"},{"key":"BFleu201612_CR4","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1182\/blood-2015-07-661983","volume":"127","author":"X Cabagnols","year":"2015","unstructured":"Cabagnols X, Favale F, Pasquier F, Messaoudi K, Defour JP, Ianotto JC et al. Presence of atypical thrombopoietin receptor (MPL) mutations in triple negative essential thrombocythemia patients. Blood 2015; 127: 333\u2013342.","journal-title":"Blood"},{"key":"BFleu201612_CR5","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1182\/blood-2015-07-661835","volume":"127","author":"JD Milosevic Feenstra","year":"2015","unstructured":"Milosevic Feenstra JD, Nivarthi H, Gisslinger H, Leroy E, Rumi E, Chachoua I et al. Whole exome sequencing identifies novel MPL and JAK2 mutations in triple negative myeloproliferative neoplasms. Blood 2015; 127: 325\u2013332.","journal-title":"Blood"},{"key":"BFleu201612_CR6","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","volume":"124","author":"E Rumi","year":"2014","unstructured":"Rumi E, Pietra D, Pascutto C, Guglielmelli P, Mart\u00ednez-Trillos A, Casetti I et al. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood 2014; 124: 1062\u20131069.","journal-title":"Blood"},{"key":"BFleu201612_CR7","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","volume":"123","author":"G Rotunno","year":"2014","unstructured":"Rotunno G, Mannarelli C, Guglielmelli P, Pacilli A, Pancrazzi A, Pieri L et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood 2014; 123: 1552\u20131555.","journal-title":"Blood"},{"key":"BFleu201612_CR8","unstructured":"Jaffe ES, Harris NL, Vardiman J, Campo E, Arber DM . Hematopathology. Elsevier Health Sciences 2010."},{"key":"BFleu201612_CR9","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe E, Pileri S, Stein H et al. WHO Classification of Tumors of the Haematopoietic and Lymphoid Tissues. IARC: Lyon, France, 2008."},{"key":"BFleu201612_CR10","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3324\/haematol.2011.047811","volume":"97","author":"T Buhr","year":"2012","unstructured":"Buhr T, Hebeda K, Kaloutsi V, Porwit A, Van der Walt J, Kreipe H . European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica 2012; 97: 360\u2013365.","journal-title":"Haematologica"},{"key":"BFleu201612_CR11","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1182\/blood-2014-12-618595","volume":"126","author":"M Lu","year":"2015","unstructured":"Lu M, Xia L, Liu YC, Hochman T, Bizzari L, Aruch D et al. Lipocalin produced by myelofibrosis cells affects the fate of both hematopoietic and marrow microenvironmental cells. Blood 2015; 126: 972\u2013982.","journal-title":"Blood"},{"key":"BFleu201612_CR12","doi-asserted-by":"publisher","first-page":"6392","DOI":"10.1182\/blood-2011-04-348144","volume":"118","author":"AG Fleischman","year":"2011","unstructured":"Fleischman AG, Aichberger KJ, Luty SB, Bumm TG, Petersen CL, Doratotaj S et al. TNF\u03b1 facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood 2011; 118: 6392\u20136398.","journal-title":"Blood"},{"key":"BFleu201612_CR13","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1158\/2159-8290.CD-14-0736","volume":"5","author":"M Kleppe","year":"2015","unstructured":"Kleppe M, Kwak M, Koppikar P, Riester M, Keller M, Bastian L et al. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Cancer Discov 2015; 5: 316\u2013331.","journal-title":"Cancer Discov"},{"key":"BFleu201612_CR14","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.ccr.2011.10.012","volume":"20","author":"D Reynaud","year":"2011","unstructured":"Reynaud D, Pietras E, Barry-Holson K, Mir A, Binnewies M, Jeanne M et al. IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development. Cancer Cell 2011; 20: 661\u2013673.","journal-title":"Cancer Cell"},{"key":"BFleu201612_CR15","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.ccell.2015.04.004","volume":"27","author":"RS Welner","year":"2015","unstructured":"Welner RS, Amabile G, Bararia D, Czibere A, Yang H, Zhang H et al. Treatment of chronic myelogenous leukemia by blocking cytokine alterations found in normal stem and progenitor cells. Cancer Cell 2015; 27: 671\u2013681.","journal-title":"Cancer Cell"},{"key":"BFleu201612_CR16","doi-asserted-by":"publisher","first-page":"8520","DOI":"10.1200\/JCO.2004.00.9316","volume":"23","author":"A Tefferi","year":"2005","unstructured":"Tefferi A . Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol 2005; 23: 8520\u20138530.","journal-title":"J Clin Oncol"},{"key":"BFleu201612_CR17","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1096\/fj.11-193078","volume":"26","author":"G Hoermann","year":"2012","unstructured":"Hoermann G, Cerny-Reiterer S, Herrmann H, Blatt K, Bilban M, Gisslinger H et al. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms. FASEB J 2012; 26: 894\u2013906.","journal-title":"FASEB J"},{"key":"BFleu201612_CR18","doi-asserted-by":"crossref","first-page":"4534","DOI":"10.1182\/blood.V88.12.4534.bloodjournal88124534","volume":"88","author":"MC Le Bousse-Kerdiles","year":"1996","unstructured":"Le Bousse-Kerdiles MC, Chevillard S, Charpentier A, Romquin N, Clay D, Smadja-Joffe F et al. Differential expression of transforming growth factor-beta, basic fibroblast growth factor, and their receptors in CD34+ hematopoietic progenitor cells from patients with myelofibrosis and myeloid metaplasia. Blood 1996; 88: 4534\u20134546.","journal-title":"Blood"},{"key":"BFleu201612_CR19","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1046\/j.1365-2141.1997.292671.x","volume":"97","author":"MC Martyre","year":"1997","unstructured":"Martyre MC, Le Bousse-Kerdiles MC, Romquin N, Chevillard S, Praloran V, Demory JL et al. Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis. Bri J Haematol 1997; 97: 441\u2013448.","journal-title":"Bri J Haematol"},{"key":"BFleu201612_CR20","doi-asserted-by":"publisher","first-page":"951","DOI":"10.2353\/ajpath.2008.071030","volume":"172","author":"O Bock","year":"2008","unstructured":"Bock O, Hoftmann J, Theophile K, Hussein K, Wiese B, Schlue J et al. Bone morphogenetic proteins are overexpressed in the bone marrow of primary myelofibrosis and are apparently induced by fibrogenic cytokines. Am J Pathol 2008; 172: 951\u2013960.","journal-title":"Am J Pathol"},{"key":"BFleu201612_CR21","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1182\/blood.V124.21.713.713","volume":"124","author":"S Verstovsek","year":"2014","unstructured":"Verstovsek S, Mesa RA, Foltz LM, Gupta V, Mascarenhas JO, Ritchie EK et al. Phase 2 trial of PRM-151, an anti-fibrotic agent, in patients with myelofibrosis: stage 1 results. Blood 2014; 124: 713\u2013713.","journal-title":"Blood"},{"key":"BFleu201612_CR22","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/j.1365-2141.2005.05674.x","volume":"130","author":"KE Panteli","year":"2005","unstructured":"Panteli KE, Hatzimichael EC, Bouranta PK, Katsaraki A, Seferiadis K, Stebbing J et al. Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. Br J Haematol 2005; 130: 709\u2013715.","journal-title":"Br J Haematol"},{"key":"BFleu201612_CR23","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1182\/blood.V78.6.1476.1476","volume":"78","author":"Z Estrov","year":"1991","unstructured":"Estrov Z, Kurzrock R, Wetzler M, Kantarjian H, Blake M, Harris D et al. Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: a novel application for inhibitors of IL-1 activity. Blood 1991; 78: 1476\u20131484.","journal-title":"Blood"},{"key":"BFleu201612_CR24","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","volume":"29","author":"A Tefferi","year":"2011","unstructured":"Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A . Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol 2011; 29: 1356\u20131363.","journal-title":"J Clin Oncol"},{"key":"BFleu201612_CR25","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1038\/leu.2013.207","volume":"27","author":"T Barbui","year":"2013","unstructured":"Barbui T, Carobbio A, Finazzi G, Guglielmelli P, Salmoiraghi S, Rosti V et al. Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis. Leukemia 2013; 27: 2084\u20132086.","journal-title":"Leukemia"},{"key":"BFleu201612_CR26","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","volume":"363","author":"S Verstovsek","year":"2010","unstructured":"Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010; 363: 1117\u20131127.","journal-title":"N Engl J Med"},{"key":"BFleu201612_CR27","doi-asserted-by":"publisher","first-page":"5264","DOI":"10.1182\/blood-2009-07-234880","volume":"114","author":"N Kroger","year":"2009","unstructured":"Kroger N, Holler E, Kobbe G, Bornhauser M, Schwerdtfeger R, Baurmann H et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 2009; 114: 5264\u20135270.","journal-title":"Blood"},{"key":"BFleu201612_CR28","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3324\/haematol.2010.031070","volume":"96","author":"T Barbui","year":"2011","unstructured":"Barbui T, Carobbio A, Finazzi G, Vannucchi AM, Barosi G, Antonioli E et al. Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica 2011; 96: 315\u2013318.","journal-title":"Haematologica"},{"key":"BFleu201612_CR29","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1182\/blood.V96.13.4261","volume":"96","author":"A Falanga","year":"2000","unstructured":"Falanga A, Marchetti M, Evangelista V, Vignoli A, Licini M, Balicco M et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 2000; 96: 4261\u20134266.","journal-title":"Blood"},{"key":"BFleu201612_CR30","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S0049-3848(02)00354-7","volume":"108","author":"T Villmow","year":"2002","unstructured":"Villmow T, Kemkes-Matthes B, Matzdorff AC . Markers of platelet activation and platelet-leukocyte interaction in patients with myeloproliferative syndromes. Thromb Res 2002; 108: 139\u2013145.","journal-title":"Thromb Res"},{"key":"BFleu201612_CR31","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.exphem.2005.01.015","volume":"33","author":"A Falanga","year":"2005","unstructured":"Falanga A, Marchetti M, Vignoli A, Balducci D, Barbui T . Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol 2005; 33: 523\u2013530.","journal-title":"Exp Hematol"},{"key":"BFleu201612_CR32","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1182\/blood-2008-02-138230","volume":"112","author":"CS Tam","year":"2008","unstructured":"Tam CS, Nussenzveig RM, Popat U, Bueso-Ramos CE, Thomas DA, Cortes JA et al. The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms. Blood 2008; 112: 1628\u20131637.","journal-title":"Blood"},{"key":"BFleu201612_CR33","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1182\/blood-2011-11-394775","volume":"119","author":"HC Hasselbalch","year":"2012","unstructured":"Hasselbalch HC . Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood 2012; 119: 3219\u20133225.","journal-title":"Blood"},{"key":"BFleu201612_CR34","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1053\/j.gastro.2005.02.027","volume":"128","author":"C Catassi","year":"2005","unstructured":"Catassi C, Bearzi I, Holmes GK . Association of celiac disease and intestinal lymphomas and other cancers. Gastroenterology 2005; 128: S79\u2013S86.","journal-title":"Gastroenterology"},{"key":"BFleu201612_CR35","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1159\/000320276","volume":"28","author":"M Lukas","year":"2010","unstructured":"Lukas M . Inflammatory bowel disease as a risk factor for colorectal cancer. Dig Dis 2010; 28: 619\u2013624.","journal-title":"Dig Dis"},{"key":"BFleu201612_CR36","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.leukres.2013.07.002","volume":"38","author":"HC Hasselbalch","year":"2014","unstructured":"Hasselbalch HC . A role of NF-E2 in chronic inflammation and clonal evolution in essential thrombocythemia, polycythemia vera and myelofibrosis? Leuk Res 2014; 38: 263\u2013266.","journal-title":"Leuk Res"},{"key":"BFleu201612_CR37","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.cytogfr.2013.01.004","volume":"24","author":"HC Hasselbalch","year":"2013","unstructured":"Hasselbalch HC . The role of cytokines in the initiation and progression of myelofibrosis. Cytokine Growth Factor Rev 2013; 24: 133\u2013145.","journal-title":"Cytokine Growth Factor Rev"},{"key":"BFleu201612_CR38","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.leukres.2012.10.020","volume":"37","author":"HC Hasselbalch","year":"2013","unstructured":"Hasselbalch HC . Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development? Leuk Res 2013; 37: 214\u2013220.","journal-title":"Leuk Res"},{"key":"BFleu201612_CR39","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1084\/jem.20110540","volume":"209","author":"KB Kaufmann","year":"2012","unstructured":"Kaufmann KB, Grunder A, Hadlich T, Wehrle J, Gothwal M, Bogeska R et al. A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2. J Exp Med 2012; 209: 35\u201350.","journal-title":"J Exp Med"},{"key":"BFleu201612_CR40","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/j.1365-2141.2005.05416.x","volume":"129","author":"PS Goerttler","year":"2005","unstructured":"Goerttler PS, Kreutz C, Donauer J, Faller D, Maiwald T, Marz E et al. Gene expression profiling in polycythaemia vera: overexpression of transcription factor NF-E2. Br J Haematol 2005; 129: 138\u2013150.","journal-title":"Br J Haematol"},{"key":"BFleu201612_CR41","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1182\/blood-2009-11-254664","volume":"116","author":"W Wang","year":"2010","unstructured":"Wang W, Schwemmers S, Hexner EO, Pahl HL . AML1 is overexpressed in patients with myeloproliferative neoplasms and mediates JAK2V617F-independent overexpression of NF-E2. Blood 2010; 116: 254\u2013266.","journal-title":"Blood"},{"key":"BFleu201612_CR42","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1084\/jem.20120521","volume":"210","author":"JS Jutzi","year":"2013","unstructured":"Jutzi JS, Bogeska R, Nikoloski G, Schmid CA, Seeger TS, Stegelmann F et al. MPN patients harbor recurrent truncating mutations in transcription factor NF-E2. J Exp Med 2013; 210: 1003\u20131019.","journal-title":"J Exp Med"},{"key":"BFleu201612_CR43","doi-asserted-by":"publisher","first-page":"101987","DOI":"10.1155\/2015\/101987","volume":"2015","author":"JS Jutzi","year":"2015","unstructured":"Jutzi JS, Pahl HL . The hen or the egg: inflammatory aspects of murine MPN models. Mediators Inflamm 2015; 2015: 101987.","journal-title":"Mediators Inflamm"},{"key":"BFleu201612_CR44","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.3324\/haematol.2012.071183","volume":"98","author":"J Wehrle","year":"2013","unstructured":"Wehrle J, Seeger TS, Schwemmers S, Pfeifer D, Bulashevska A, Pahl HL . Transcription factor nuclear factor erythroid-2 mediates expression of the cytokine interleukin 8, a known predictor of inferior outcome in patients with myeloproliferative neoplasms. Haematologica 2013; 98: 1073\u20131080.","journal-title":"Haematologica"},{"key":"BFleu201612_CR45","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.exphem.2010.05.005","volume":"38","author":"R Roelz","year":"2010","unstructured":"Roelz R, Pilz IH, Mutschler M, Pahl HL . Of mice and men: human RNA polymerase III promoter U6 is more efficient than its murine homologue for shRNA expression from a lentiviral vector in both human and murine progenitor cells. Exp Hematol 2010; 38: 792\u2013797.","journal-title":"Exp Hematol"},{"key":"BFleu201612_CR46","doi-asserted-by":"publisher","first-page":"e74974","DOI":"10.1371\/journal.pone.0074974","volume":"8","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, Liu X, McHale C, Li R, Zhang L, Wu Y et al. Bone marrow injury induced via oxidative stress in mice by inhalation exposure to formaldehyde. PLoS One 2013; 8: e74974.","journal-title":"PLoS One"},{"key":"BFleu201612_CR47","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/nature15252","volume":"525","author":"Q Zhang","year":"2015","unstructured":"Zhang Q, Zhao K, Shen Q, Han Y, Gu Y, Li X et al. Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6. Nature 2015; 525: 389\u2013393.","journal-title":"Nature"},{"issue":"1","key":"BFleu201612_CR48","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/ejh.12684","volume":"97","author":"Anders Lindholm S\u00f8rensen","year":"2015","unstructured":"Sorensen AL, Hasselbalch HC . Smoking and Philadelphia-negative chronic myeloproliferative neoplasms. Eur J Haematol 2015; e-pub ahead of print 18 September 2015 doi:10.1111\/ejh.12684.","journal-title":"European Journal of Haematology"},{"key":"BFleu201612_CR49","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1586\/ehm.12.69","volume":"6","author":"RT Silver","year":"2013","unstructured":"Silver RT, Kiladjian JJ, Hasselbalch HC . Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis. Expert Rev Hematol 2013; 6: 49\u201358.","journal-title":"Expert Rev Hematol"},{"key":"BFleu201612_CR50","doi-asserted-by":"crossref","unstructured":"Utke Rank C, Weis Bjerrum O, Larsen TS, Kj\u00e6r L, de Stricker K, Riley CH et al. Minimal residual disease after long-term interferon-alpha2 treatment. A report on hematological, molecular, and histomorphological response patterns in ten patients with essential thrombocythemia and polycythemia vera. Leuk Lymph 2015; e-pub ahead of print 18 June 2015.","DOI":"10.3109\/10428194.2015.1049171"},{"key":"BFleu201612_CR51","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1182\/blood-2015-03-635235","volume":"126","author":"M Deininger","year":"2015","unstructured":"Deininger M, Radich J, Burn TC, Huber R, Paranagama D, Verstovsek S . The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis. Blood 2015; 126: 1551\u20131554.","journal-title":"Blood"},{"key":"BFleu201612_CR52","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012; 366: 799\u2013807.","journal-title":"N Engl J Med"},{"key":"BFleu201612_CR53","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012; 366: 787\u2013798.","journal-title":"N Engl J Med"},{"key":"BFleu201612_CR54","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1056\/NEJMoa1409002","volume":"372","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 2015; 372: 426\u2013435.","journal-title":"N Engl J Med"},{"key":"BFleu201612_CR55","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ccell.2015.06.006","volume":"28","author":"SC Meyer","year":"2015","unstructured":"Meyer SC, Keller MD, Chiu S, Koppikar P, Guryanova OA, Rapaport F et al. CHZ868, a type II JAK2 inhibitor, reverses type I JAK inhibitor persistence and demonstrates efficacy in myeloproliferative neoplasms. Cancer Cell 2015; 28: 15\u201328.","journal-title":"Cancer Cell"},{"key":"BFleu201612_CR56","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1182\/blood-2014-01-547760","volume":"123","author":"N Bhagwat","year":"2014","unstructured":"Bhagwat N, Koppikar P, Keller M, Marubayashi S, Shank K, Rampal R et al. Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms. Blood 2014; 123: 2075\u20132083.","journal-title":"Blood"},{"key":"BFleu201612_CR57","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.beha.2014.07.009","volume":"27","author":"J Mascarenhas","year":"2014","unstructured":"Mascarenhas J . Rationale for combination therapy in myelofibrosis. Best Pract Res Clin Haematol 2014; 27: 197\u2013208.","journal-title":"Best Pract Res Clin Haematol"},{"key":"BFleu201612_CR58","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S0092-8674(00)81166-6","volume":"93","author":"SJ Rodig","year":"1998","unstructured":"Rodig SJ, Meraz MA, White JM, Lampe PA, Riley JK, Arthur CD et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 1998; 93: 373\u2013383.","journal-title":"Cell"},{"key":"BFleu201612_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0378-1119(02)00398-0","volume":"285","author":"T Kisseleva","year":"2002","unstructured":"Kisseleva T, Bhattacharya S, Braunstein J, Schindler CW . Signaling through the JAK\/STAT pathway, recent advances and future challenges. Gene 2002; 285: 1\u201324.","journal-title":"Gene"},{"key":"BFleu201612_CR60","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1200\/JCO.2010.32.8021","volume":"29","author":"A Pardanani","year":"2011","unstructured":"Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 2011; 29: 789\u2013796.","journal-title":"J Clin Oncol"},{"key":"BFleu201612_CR61","first-page":"663","volume":"122","author":"J Mascarenhas","year":"2013","unstructured":"Mascarenhas J, Talpaz M, Gupta V, Savona M, Coughlin P, Winton E et al. An open-label, phase II study of the JAK1 inhibitor INCB039110 in patients with myelofibrosis. Blood 2013; 122: 663\u2013663.","journal-title":"Blood"},{"key":"BFleu201612_CR62","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.1182\/blood-2010-08-258772","volume":"117","author":"J-J Kiladjian","year":"2011","unstructured":"Kiladjian J-J, Mesa RA, Hoffman R . The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood 2011; 117: 4706\u20134715.","journal-title":"Blood"},{"key":"BFleu201612_CR63","doi-asserted-by":"publisher","first-page":"6669","DOI":"10.1182\/blood-2010-11-320069","volume":"117","author":"RT Silver","year":"2011","unstructured":"Silver RT, Vandris K, Goldman JJ . Recombinant interferon-alpha may retard progression of early primary myelofibrosis: a preliminary report. Blood 2011; 117: 6669\u20136672.","journal-title":"Blood"},{"key":"BFleu201612_CR64","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1038\/modpathol.2015.93","volume":"28","author":"M Pizzi","year":"2015","unstructured":"Pizzi M, Silver RT, Barel A, Orazi A . Recombinant interferon-alpha in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response. Mod Pathol 2015; 28: 1315\u20131323.","journal-title":"Mod Pathol"},{"key":"BFleu201612_CR65","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1182\/blood-2013-04-498956","volume":"122","author":"S Hasan","year":"2013","unstructured":"Hasan S, Lacout C, Marty C, Cuingnet M, Solary E, Vainchenker W et al. JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFN\u03b1. Blood 2013; 122: 1464\u20131477.","journal-title":"Blood"},{"key":"BFleu201612_CR66","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.1182\/blood-2012-05-432989","volume":"121","author":"A Mullally","year":"2013","unstructured":"Mullally A, Bruedigam C, Poveromo L, Heidel FH, Purdon A, Vu T et al. Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-\u03b1 in a murine model of polycythemia vera. Blood 2013; 121: 3692\u20133702.","journal-title":"Blood"},{"key":"BFleu201612_CR67","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.exphem.2010.03.005","volume":"38","author":"M Lu","year":"2010","unstructured":"Lu M, Zhang W, Li Y, Berenzon D, Wang X, Wang J et al. Interferon-alpha targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway. Exp Hematol 2010; 38: 472\u2013480.","journal-title":"Exp Hematol"},{"key":"BFleu201612_CR68","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011; 29: 761\u2013770.","journal-title":"J Clin Oncol"},{"key":"BFleu201612_CR69","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1586\/17474086.2013.876356","volume":"7","author":"HC Hasselbalch","year":"2014","unstructured":"Hasselbalch HC . Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms. Expert Rev Hematol 2014; 7: 203\u2013216.","journal-title":"Expert Rev Hematol"},{"key":"BFleu201612_CR70","first-page":"73","volume":"3","author":"ME Bjorn","year":"2014","unstructured":"Bjorn ME, de Stricker K, Kjaer L, Ellemann K, Hasselbalch HC . Combination therapy with interferon and JAK1-2 inhibitor is feasible: proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera. Leuk Res Rep 2014; 3: 73\u201375.","journal-title":"Leuk Res Rep"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu201612.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201612","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/leu.2016.12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/leu201612.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T16:15:55Z","timestamp":1648743355000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu201612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,8]]},"references-count":70,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["BFleu201612"],"URL":"https:\/\/doi.org\/10.1038\/leu.2016.12","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,8]]},"assertion":[{"value":"30 October 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Steffen Koschmieder: research funding (Novartis and Novartis Foundation); consultancy and advisory boards (Ariad, AOP, Baxalta, Bristol-Myers Squibb, CTI, Novartis, Pfizer, Sanofi); honoraria and travel grants (Ariad, Alexion, AOP, Baxalta, Bristol-Myers Squibb, Celgene, CTI, Novartis, Pfizer, Sanofi, Shire). Hans C Hasselbalch: research grant (Novartis). Peter Valent: honoraria (Novartis, Ariad, Pfizer und BMS); grant support (Novartis, Ariad); consultancy (Novartis Global PKC412 Trial). Heike Pahl: consultancy and advisory boards (AOP, Baxalta, Novartis, Shire). R\u00fcdiger Hehlmann: research funding (BMS and Novartis). Alessandro Vannucchi: honoraria for advisory board and speaker fees (Novartis). Francisco Cervantes: advisory board (Novartis, AOP, and CTI-Baxter); speakers bureau (Novartis and CTI-Baxter).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}